 CSL further claims that those general practitioners who received the GSKA Information Sheet would understand it to be saying that CERVARIX was a superior vaccine to GARDASIL because it offered greater benefits. 24 The evidence is that the GSKA Information Sheet was distributed to at least 300 general practitioners.
 He said that the GSKA Information Sheet, and the representations contained therein would have no impact or affect on CSL's application for such funding. 74 Mr Herd said that GSKA would itself suffer irreparable harm if interlocutory relief were granted to CSL.
